LJPC La Jolla Pharmaceutical Company

5.99
-0.05  -1%
Previous Close 6.04
Open 6.35
Price To Book 2.29
Market Cap 157139450
Shares 26,233,631
Volume 889,800
Short Ratio
Av. Daily Volume 933,935

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019.
LJPC‑401
Hereditary Hemochromatosis
Pivotal data due mid-2020.
LJPC-401
Beta thalassemia patients suffering from iron overload
PDUFA date under priority review scheduled for February 28, 2018. Approval announced December 21, 2017.
GiaprezaTM (angiotensin II)
Increase blood pressure in adults with septic or other distributive shock

Latest News

  1. Large Biotech Stock Holder Slashes Stake, but Insiders Are Buying
  2. Biotech Companies to Watch
  3. HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance
  4. Here's Why La Jolla Pharmaceutical Tumbled Today
  5. La Jolla Stock Plummets 44% After Disappointing Drug Sales Projections
  6. La Jolla Pharmaceutical's stock plummets to pace Nasdaq losers after downbeat drug guidance
  7. La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
  8. La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
  9. Hedge Funds Are Crazy About La Jolla Pharmaceutical Company (LJPC)
  10. Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  11. Edited Transcript of LJPC earnings conference call or presentation 24-Oct-18 8:30pm GMT
  12. 3 Healthcare Stocks To Watch On Thursday
  13. La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
  14. La Jolla Pharmaceutical: 3Q Earnings Snapshot
  15. The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering
  16. Why You Need To Look At This Factor Before Buying La Jolla Pharmaceutical Company (NASDAQ:LJPC)